Preclinical research published in Vaccines demonstrates Infectimune® significantly improved quantity and quality of potent multifunctional CD4 T cells compared to...
Company expects enrollment in Phase 1 proof-of-concept study of DNA-based vaccine technology to begin in Q2The application follows guidance provided...
SALT LAKE CITY, UT / ACCESSWIRE / March 12, 2024 / CenExel, a leading clinical research site network with 18...
The first Mitral Valve Replacement using the Made in India SSi Mantra Surgical Robotic System was successfully performed at the...
KNOXVILLE, TN, March 12, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today announced that...
Represents a $0.15 Per Share Increase Over 2023 Special DividendNEW YORK, March 12, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc....
A review of Russian and English literature suggests that Appili’s biodefense program ATI-1701 may have a role in preventing tularemia...
Safety in the Phase 1b part of Sonnet's double-blind, randomized, controlled trial of SON‑080 was reviewed by the study's Data...
Interchangeability study for HADLIMA (adalimumab-bwwd) was conducted in accordance with the FDA’s Guidance for Industry; primary pharmacokinetics (PK) endpoints as...
VANCOUVER, BC, March 8, 2024 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (the "Company") today announced...
Conference call to begin at 4:30 p.m. ETSOUTH SAN FRANCISCO, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ:...
Agreement with a leading cancer treatment group to advance the clinical development of Bria-OTS+ (breast cancer) and Bria-PROS+ (prostate cancer),...
HORSHAM, Pa., March 07, 2024 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology...
Moffitt’s preclinical findings strongly suggest PV-10 induces immunogenic cell death-associated immunogenicity in HPV-positive and HPV-negative HNSCC in vitro and in...
Sharps and Roncadelle are Joining Forces to Sell and Distribute their Securegard, SAFER, and Sologard Lines of Disposable Smart Safety...
Mainz, Germany, March 7, 2024 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) announced today that Sean...
• Study delivers first clinical safety and pharmacokinetic data as proof of concept for the use of multispecific antibodies in humans•...
Directed at individuals who may be at risk of elevated PFAS exposure, the new test detects and measures PFAS identified...
-- Company Expects to Announce Topline Safety, Tolerability and Immunogenicity Data from Primary Immunization Series by the End of the...
Vancouver, British Columbia--(Newsfile Corp. - March 4, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or...